Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown
BioCentury This Week
English - April 26, 2022 01:00 - 20 minutes - 14.4 MB - ★★★★★ - 11 ratingsScience biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Next Episode: Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO
The first clinical data from Nkarta’s CAR natural killer cell platform add to the growing evidence that a CAR may provide the efficacy boost NK cell therapies have needed. BioCentury's editors analyze the significance of the data, which drove a 141% gain in the biotech's stock. They also discuss the biopharma legacy of the late Sen. Orrin Hatch, how biopharma companies are coping with the extended lockdown in Shanghai, and takeaways from J.P. Morgan’s Mike Gaito appearance on The BioCentury Show. This week’s podcast is sponsored by Kendall Square Orchestra.